Teleflex Incorporated
TFXTeleflex Incorporated (TFX) is a global provider of medical technologies focused on solutions for healthcare providers and patients. Founded in 1943, the company specializes in products used in minimally invasive surgeries, anesthesiology, respiratory care, and vascular access, offering a broad portfolio aimed at improving clinical outcomes and healthcare efficiency. Its innovations support hospitals, clinics, and other medical facilities worldwide.
Dividend History
Investors can expect a dividend payout of $0.34 per share, scheduled to be distributed in 7 days on December 15, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 15, 2025 | $0.34 | 2025-11-14 | 2025-11-14 |
| September 15, 2025 | $0.34 | 2025-08-15 | 2025-08-15 |
| June 16, 2025 | $0.34 | 2025-05-20 | 2025-05-20 |
| March 17, 2025 | $0.34 | 2025-03-07 | 2025-03-07 |
| December 16, 2024 | $0.34 | 2024-11-15 | 2024-11-15 |
Dividends Summary
- Teleflex Incorporated has issued 89 dividend payments over the past 22 years
- The most recent dividend was paid 84 days ago, on September 15, 2025
- The highest dividend payed out to investors during this period was $0.34 per share
- The average dividend paid during this period was $0.32 per share.
Company News
The U.S. arteriovenous fistula devices market is projected to grow from $112 million in 2025 to $120 million by 2033, driven by rising end-stage renal disease cases and increasing demand for advanced vascular access solutions.
Teleflex has completed its acquisition of BIOTRONIK's Vascular Intervention business for €760 million, expanding its global presence in the cath lab and peripheral intervention market with a comprehensive portfolio of medical technologies.
Several S&P 500 stocks posted sharp declines in 2024, despite a generally bullish year for the index. These battered stocks could be ripe for a turnaround in 2025, as investors look for undervalued gems in the market.
Phibro Animal Health Corporation's robust sales of vaccines and medicated feed additives (MFAs) are driving growth in its Animal Health business. The company's focus on advancing nutritional specialties and vaccine technologies, along with a new vaccine production unit, instills optimism. However, adverse macroeconomic impacts and growing competi...
